Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Acerand Therapeutics (Hong Kong) Limited currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action. This concentration suggests a highly specific prosecution strategy where all active matters are consolidated under 1 distinct art unit.
The busiest examiner for this portfolio is AULAKH, CHARANJIT, who is responsible for 1 pending office action. Because the total number of distinct examiners is 1, this individual accounts for the entirety of the company's current workload. This specific ratio between pending actions and examiners indicates that the portfolio's current activity is limited to 1 point of contact.
The alignment of 1 distinct examiner and 1 distinct art unit reflects a streamlined administrative footprint. Practitioners can expect a consistent approach to prosecution given that the busiest examiner, AULAKH, CHARANJIT, manages the only active matter. This structure minimizes the complexity often found in larger portfolios distributed across multiple art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506062 | SOS1 INHIBITORS | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506062 | SOS1 INHIBITORS | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Nov 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcerand Therapeutics (Hong Kong) Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of Acerand Therapeutics (Hong Kong) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
